Market research
AZRX AzurRx BioPharma Inc
NASDAQ USD Healthcare
Latest close
As of 05 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 34M
- P/E ratio
- Not available
- Analyst target
- 16
- Dividend yield
- 0.0%
- Beta
- 1.51
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 34M
- P/E ratio
- Not available
- Analyst target
- 16
- Dividend yield
- 0.0%
- Beta
- 1.51
About
About AzurRx BioPharma Inc
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is based in Boca Raton, Florida.
Research context
AzurRx BioPharma Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the AZRX discussion.
5 years, 6 months ago
AzurRx BioPharma, Inc is currently in a long term downtrend where the price is trading 20.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
AzurRx BioPharma, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 1257.7% to $-17M since the same quarter in the previous year.
Finally, its free cash flow fell by 82.2% to $-6M since the same quarter in the previous year.
Based on the above factors, AzurRx BioPharma, Inc gets an overall score of 1/5.